CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Organovo Holdings, Inc. - ONVO CFD

1.08
4.42%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.13
Open* 1.09
1-Year Change* -48.83%
Day's Range* 1.08 - 1.14
52 wk Range 1.00-3.40
Average Volume (10 days) 113.04K
Average Volume (3 months) 4.72M
Market Cap 10.20M
P/E Ratio -100.00K
Shares Outstanding 9.81M
Revenue 368.00K
EPS -2.15
Dividend (Yield %) N/A
Beta 0.91
Next Earnings Date Feb 8, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 19, 2024 1.08 -0.01 -0.92% 1.09 1.16 1.07
Apr 18, 2024 1.13 0.09 8.65% 1.04 1.26 1.04
Apr 17, 2024 1.14 0.05 4.59% 1.09 1.18 1.03
Apr 16, 2024 1.16 -0.09 -7.20% 1.25 1.26 1.09
Apr 15, 2024 1.30 -0.36 -21.69% 1.66 1.71 1.18
Apr 12, 2024 0.99 0.00 0.00% 0.99 1.00 0.98
Apr 11, 2024 1.01 0.02 2.02% 0.99 1.01 0.99
Apr 10, 2024 1.01 0.02 2.02% 0.99 1.01 0.99
Apr 9, 2024 1.01 0.00 0.00% 1.01 1.02 1.01
Apr 8, 2024 1.02 0.02 2.00% 1.00 1.02 1.00
Apr 5, 2024 1.00 0.00 0.00% 1.00 1.02 0.99
Apr 4, 2024 1.02 0.04 4.08% 0.98 1.03 0.98
Apr 3, 2024 1.01 0.01 1.00% 1.00 1.02 0.98
Apr 2, 2024 1.00 0.02 2.04% 0.98 1.00 0.98
Apr 1, 2024 1.00 0.00 0.00% 1.00 1.00 0.99
Mar 28, 2024 1.01 0.02 2.02% 0.99 1.02 0.99
Mar 27, 2024 0.99 -0.01 -1.00% 1.00 1.03 0.99
Mar 26, 2024 1.02 0.03 3.03% 0.99 1.06 0.97
Mar 25, 2024 1.01 0.03 3.06% 0.98 1.17 0.98
Mar 22, 2024 0.99 0.02 2.06% 0.97 0.99 0.97

Organovo Holdings, Inc. Events

Time (UTC) Country Event
Thursday, July 11, 2024

Time (UTC)

20:00

Country

US

Event

Q4 2023 Organovo Holdings Inc Earnings Release
Q4 2023 Organovo Holdings Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total revenue 0.37 1.5 0 2.196 3.091
Revenue 0.37 1.5 0 2.196 3.091
Cost of Revenue, Total 0 0.328 0.482
Gross Profit 0 1.868 2.609
Total Operating Expense 18.101 12.979 16.826 23.671 30.365
Selling/General/Admin. Expenses, Total 9.088 9.631 12.9 14.423 15.131
Research & Development 8.72 3.206 1.077 5.051 14.752
Operating Income -17.731 -11.479 -16.826 -21.475 -27.274
Interest Income (Expense), Net Non-Operating 0.483 0.008 0.015 0.594 0.705
Gain (Loss) on Sale of Assets -0.009 0 -0.019 0.113 -0.063
Net Income Before Taxes -17.257 -11.446 -16.824 -18.708 -26.632
Net Income After Taxes -17.259 -11.448 -16.826 -18.71 -26.635
Net Income Before Extra. Items -17.259 -11.448 -16.826 -18.71 -26.635
Net Income -17.259 -11.448 -16.826 -18.71 -26.635
Income Available to Common Excl. Extra. Items -17.259 -11.448 -16.826 -18.71 -26.635
Income Available to Common Incl. Extra. Items -17.259 -11.448 -16.826 -18.71 -26.635
Diluted Net Income -17.259 -11.448 -16.826 -18.71 -26.635
Diluted Weighted Average Shares 8.71303 8.7036 6.902 6.47781 5.769
Diluted EPS Excluding Extraordinary Items -1.98083 -1.31532 -2.43784 -2.88832 -4.61692
Diluted Normalized EPS -1.98015 -1.31532 -2.17161 -2.62603 -4.60982
Other, Net 0 0.025 0.006 2.06 0
Total Extraordinary Items
Depreciation / Amortization 0.293 0.142 0.041 1.142
Unusual Expense (Income) 0 2.808 2.727
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.075 0.162 0.131 0.077 0
Revenue 0.075 0.162 0.131 0.077
Cost of Revenue, Total
Gross Profit
Total Operating Expense 4.27 7.941 3.49 3.431 3.239
Selling/General/Admin. Expenses, Total 2.591 2.478 2.22 2.185 2.205
Research & Development 1.612 5.404 1.14 1.191 0.984
Depreciation / Amortization 0.067 0.059 0.13 0.055 0.05
Unusual Expense (Income)
Operating Income -4.195 -7.779 -3.359 -3.354 -3.239
Interest Income (Expense), Net Non-Operating 0.169 0.329 0.095 0.033 0.026
Gain (Loss) on Sale of Assets -0.009
Other, Net 0 0 0 0
Net Income Before Taxes -4.026 -7.459 -3.264 -3.321 -3.213
Net Income After Taxes -4.028 -7.459 -3.264 -3.321 -3.215
Net Income Before Extra. Items -4.028 -7.459 -3.264 -3.321 -3.215
Net Income -4.028 -7.459 -3.264 -3.321 -3.215
Income Available to Common Excl. Extra. Items -4.028 -7.459 -3.264 -3.321 -3.215
Income Available to Common Incl. Extra. Items -4.028 -7.459 -3.264 -3.321 -3.215
Diluted Net Income -4.028 -7.459 -3.264 -3.321 -3.215
Diluted Weighted Average Shares 8.71723 8.71525 8.71362 8.71228 8.71097
Diluted EPS Excluding Extraordinary Items -0.46207 -0.85586 -0.37459 -0.38119 -0.36907
Diluted Normalized EPS -0.46207 -0.85482 -0.37459 -0.38119 -0.36907
Dividends per Share - Common Stock Primary Issue 0 0 0 0
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total Current Assets 17.048 29.533 38.398 28.318 38.574
Cash and Short Term Investments 16.007 28.675 37.364 27.356 36.477
Cash & Equivalents 15.301 28.675 37.364 27.356 36.477
Total Receivables, Net 0.152 0 0.111 0.558
Accounts Receivable - Trade, Net 0.152 0 0.111 0.503
Total Inventory 0 0.49
Prepaid Expenses 0.889 0.858 1.034 0.851 1.049
Total Assets 20.313 33.296 39.917 28.441 40.623
Property/Plant/Equipment, Total - Net 2.607 2.815 0.381 0 1.832
Property/Plant/Equipment, Total - Gross 3.883 3.886 1.383 0.415 6.413
Accumulated Depreciation, Total -1.276 -1.071 -1.002 -0.415 -4.581
Intangibles, Net 0.013 0.094 0.109 0.123 0.137
Other Long Term Assets, Total 0.645 0.854 1.029 0 0.08
Total Current Liabilities 3.671 1.383 0.721 1.81 3.737
Accounts Payable 0.331 0.415 0.281 0.72 0.628
Accrued Expenses 3.34 0.968 0.44 1.09 2.584
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0 0.525
Total Liabilities 4.984 3.087 0.721 1.81 4.325
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 1.313 1.704 0 0.588
Total Equity 15.329 30.209 39.196 26.631 36.298
Common Stock 0.009 0.009 0.009 0.131 0.124
Additional Paid-In Capital 340.317 337.94 335.479 305.965 296.929
Retained Earnings (Accumulated Deficit) -324.998 -307.739 -296.291 -279.465 -260.755
Other Equity, Total 0.002
Total Liabilities & Shareholders’ Equity 20.313 33.296 39.917 28.441 40.623
Total Common Shares Outstanding 8.71691 8.71063 8.67049 6.52791 6.20077
Treasury Stock - Common -0.001 -0.001 -0.001
Short Term Investments 0.706
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 8.296 11.695 17.048 21.614 24.357
Cash and Short Term Investments 7.617 10.754 16.007 20.75 23.838
Cash & Equivalents 7.617 10.754 15.301 20.196 13.265
Total Receivables, Net 0.055 0.149 0.152 0.076
Accounts Receivable - Trade, Net 0.055 0.149 0.152 0.076
Prepaid Expenses 0.624 0.792 0.889 0.788 0.519
Total Assets 11.161 14.756 20.313 25.079 27.91
Property/Plant/Equipment, Total - Net 2.313 2.456 2.607 2.545 2.716
Other Long Term Assets, Total 0.552 0.605 0.658 0.92 0.837
Total Current Liabilities 1.6 1.77 3.671 1.376 1.389
Accounts Payable 0.435 0.488 0.331 0.242 0.441
Accrued Expenses 1.165 1.282 3.34 1.134 0.948
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 2.705 2.98 4.984 2.79 2.904
Total Long Term Debt 0 0 0 0 0
Total Equity 8.456 11.776 15.329 22.289 25.006
Common Stock 0.009 0.009 0.009 0.009 0.009
Additional Paid-In Capital 341.467 340.792 340.317 339.817 339.273
Retained Earnings (Accumulated Deficit) -333.02 -329.026 -324.998 -317.539 -314.275
Treasury Stock - Common -0.001 -0.001 -0.001 -0.001 -0.001
Total Liabilities & Shareholders’ Equity 11.161 14.756 20.313 25.079 27.91
Total Common Shares Outstanding 8.71945 8.7182 8.71691 8.71459 8.71327
Other Liabilities, Total 1.105 1.21 1.313 1.414 1.515
Short Term Investments 0 0 0.706 0.554 10.573
Other Equity, Total 0.001 0.002 0.002 0.003
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -11.448 -16.826 -18.71 -26.635 -34.803
Cash From Operating Activities -8.453 -13.323 -14.882 -20.375 -28.857
Cash From Operating Activities 0.142 0.041 1.142 0.98 1.267
Non-Cash Items 2.256 5.575 3.684 5.13 6.767
Cash Taxes Paid 0.002 -0.002 -0.002 -0.003 0.002
Changes in Working Capital 0.597 -2.113 -0.998 0.15 -2.088
Cash From Investing Activities -0.409 -0.393 0.747 -0.076 -0.292
Capital Expenditures -0.409 -0.405 0 -0.079 -0.296
Other Investing Cash Flow Items, Total 0 0.012 0.747 0.003 0.004
Cash From Financing Activities 0.205 23.835 4.935 13.154 10.113
Issuance (Retirement) of Stock, Net 0.251 23.839 4.996 13.377 10.113
Issuance (Retirement) of Debt, Net 0
Foreign Exchange Effects 0 0.011
Net Change in Cash -8.657 10.119 -9.2 -7.297 -19.025
Financing Cash Flow Items -0.046 -0.004 -0.061 -0.223
Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
Net income/Starting Line -9.8 -6.536 -3.215 -11.448 -9.537
Cash From Operating Activities -7.675 -4.631 -2.414 -8.453 -6.912
Cash From Operating Activities 0.234 0.104 0.05 0.142 0.096
Non-Cash Items 1.896 1.346 0.655 2.256 1.429
Cash Taxes Paid 0.002 0.002 0.002 0.002 0.002
Changes in Working Capital -0.005 0.455 0.096 0.597 1.1
Cash From Investing Activities -0.804 -10.779 -10.693 -0.409 -0.356
Capital Expenditures -0.234 -0.193 -0.074 -0.409 -0.356
Other Investing Cash Flow Items, Total -0.57 -10.586 -10.619 0 0
Cash From Financing Activities 0 0 0 0.205 0.205
Financing Cash Flow Items 0 0 -0.046 -0.046
Issuance (Retirement) of Stock, Net 0 0 0 0.251 0.251
Net Change in Cash -8.479 -15.41 -13.107 -8.657 -7.063

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Organovo Holdings, Inc. Company profile

About Organovo Holdings Inc

Organovo Holdings, Inc. is an early stage biotechnology company. The Company is focused on building high fidelity, three-dimensional (3D) tissues that recapitulate key aspects of human disease. The Company is targeting the intestine and has ongoing 3D tissue developments in Ulcerative colitis (UC) and Crohn's disease (CD). The Company uses its platform technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. NovoGen Bioprinters can dispense pure hydrogel formulations and also serve as important components of company's tissue prototyping and manufacturing platform. The Company also intends to use its bioprinting platform as well as 3D technologies to treat its target diseases.

Financial summary

BRIEF: For the nine months ended 31 December 2021, Organovo Holdings Inc revenues was not reported. Net loss decreased 33% to $9.5M. Lower net loss reflects Non-cash stock-based compensation decrease of 78% to $1.2M (expense), Gain (loss) on fixed asset disposals decrease from $19K (expense) to $0K, Other income increase from $6K to $25K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$2.15 to -$1.10.

Equity composition

Common Stock $.0001 Par, 06/12 Shares auth.75M and o/s 43,772,483. Insiders 39.83%. 02/12, 10.59135-for-1 Stock split.

Industry: Biotechnology & Medical Research (NEC)

Suite 110
6275 Nancy Ridge Drive
SAN DIEGO
CALIFORNIA 92121
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

BTC/USD

65,339.10 Price
+0.650% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,392.09 Price
+0.540% 1D Chg, %
Long position overnight fee -0.0192%
Short position overnight fee 0.0110%
Overnight fee time 21:00 (UTC)
Spread 0.40

XRP/USD

0.54 Price
+0.480% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

US100

17,037.80 Price
-1.980% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading